雷替曲塞联合顺铂在原发性肝癌肝动脉化疗栓塞术中的应用价值分析  

Application Value of Raltitrexed Combined with Cisplatin in Transcatheter Arterial Chemoembolization for Primary Liver Cancer

作　　者：王洪伟 安萃萃 刘超[1] 海青 WANG Hongwei;AN Cuicui;LIU Chao;LI Haiqing(Department of Minimally Invasive Oncology,Tai'an Central Hospital,Tai'an,Shandong Province,271000 China)

机构地区：[1]山东省泰安市中心医院肿瘤微创科,山东泰安271000

出　　处：《中外医疗》2023年第28期60-63,共4页China & Foreign Medical Treatment

摘　　要：目的分析原发性肝癌(primary liver cancer,PLC)肝动脉化疗栓塞术(transcatheter arterial chemoemboli‐zation,TACE)中雷替曲塞联合顺铂的应用价值。方法回顾性分析入2021年1月—2022年12月于山东省泰安市中心医院确诊为PLC接受TACE治疗的62例患者的临床资料,对照组30例单独使用顺铂栓塞化疗,研究组32例选择雷替曲塞+顺铂栓塞化疗。对比不同治疗方案对肝功能、血清肿瘤标志物的影响以及用药安全性及患者预后情况。结果治疗后研究组疾病控制率高于对照组,总胆红素、谷丙转氨酶、甲胎蛋白、癌胚抗原水平均低于对照组,差异有统计学意义(P<0.05)。研究组1年内存活率为87.50%,高于对照组的63.33%,差异有统计学意义(χ^(2)=4.931,P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论PLC接受雷替曲塞联合顺铂TACE治疗总体效果理想,不但能够一定程度改善肝功能,还能够提升肿瘤控制效果,延长患者存活期,用药安全性上有保障,值得推广运用。Objective To analyze the application value of ratitrexed combined with cisplatin in transcatheter arterial chemoembolization(TACE)of primary liver cancer(PLC).Methods The clinical data of 62 patients diagnosed with PLC who received TACE treatment in Tai'an Central Hospital of Shandong Province from January 2021 to December 2022 were retrospectively analyzed.30 patients in the control group received cisplatin embolization chemotherapy alone,while 32 patients in the study group received ratitrexide plus cisplatin embolization chemotherapy.The effects of different treatment regimens on liver function,serum tumor markers,drug safety and patient prognosis were compared.Results After treatment,the disease control rate of the study group was higher than that of the control group,and the levels of total bilirubin,alanine aminotransferase,A-fetoprotein and carcinoembryonic antigen were lower than those of the control group,the difference was statistically significant(P<0.05).The 1-year survival rate of the study group was 87.50%,higher than that of the control group(63.33%),and the difference was statistically significant(χ^(2)=4.931,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The overall effect of PLC treatment with ratitrexed combined with cisplatin TACE is ideal,which can not only improve liver function to a certain extent,but also improve tumor control effect,prolong patient survival,and guarantee drug safety,which is worthy of promotion and application.

关 键 词：雷替曲塞 顺铂 原发性肝癌 肝动脉化疗栓塞 存活率 

分 类 号：R246.5[医药卫生—针灸推拿学]